HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Alliance of Beauty.com - "one of the fastest growing prestige beauty e-commerce sites" - and online designer clothing retailer Bluefly.com will provide " an all-encompassing prestige beauty and fashion experience" as the two seek to "intrigue" consumers with behind-the-scene trend videos and special promotions, according to Oct. 10 release. "Fashion and beauty have always been closely linked but rarely co-merchandised - especially online," Bluefly.com Chief Marketing Officer Bradford Matson notes. VP-Beauty for Beauty.com Kathleen McNeill states: "Beauty is an integral part of the fashion world, and the right choice of color cosmetics and hair will enhance any style of clothing." Consumers now can "get the perfect dress to wear with that new shade of red lipstick," she says, stressing the convenience of being able to assemble "head-to-toe looks with a few quick clicks." Currently viewable at the two sites is an inside look at a Bluefly photo shoot, as well as expert hair-styling instruction and makeup application tips...

You may also be interested in...

Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.

COVID-19 Shows Remote Monitoring Can Work For Pre-Cert Program

In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts